Expert Interview
A Second Look: Exploring the Future of Polycythemia Vera Treatment: A Deep Dive into Protagonist Therapeutics, Inc.'s Rusfertide (PTG-300) Development.
Ticker(s): PTGXInstitution: Mount Sinai
- Assistant Professor at the Mount Sinai Health System (Icahn School of Medicine).
- Manages 40-50 patients with MF currently and is familiar with the MOMENTUM trial.
- Research interests include myeloproliferative neoplasms, especially polycythemia vera and myelofibrosis, as well as acute myeloid leukemia, hemophagocytic lymphohistiocytosis, systemic mastocytosis, and chronic myelomonocytic leukemia and has published extensively on these topics.
Considering the 2-year follow-up data from the REVIVE study, can you elaborate on the long-term efficacy of Rusfertide in maintaining hematocrit control in PV patients, especially in comparison to traditional phlebotomy methods?
Added By: kyle_adminHow has Rusfertide impacted the frequency of phlebotomy and serum ferritin levels in PV patients over the course of the study?
Added By: kyle_adminBased on the REVIVE study, how would you characterize the safety profile of Rusfertide, particularly in relation to injection site reactions and the prevalence of cancer among participants?
Added By: kyle_adminHow does Rusfertide compare with standard PV treatments like hydroxyurea, especially in terms of efficacy and safety?
Added By: kyle_adminWhat insights can you provide about the impact of Rusfertide on patient-reported outcomes and overall quality of life for PV patients?
Added By: kyle_adminIn light of the findings that high-risk PV patients (with prior thromboembolic events) did not experience recurrent TEs while on Rusfertide, what implications does this have for managing this subgroup of patients?
Added By: kyle_adminGiven the promising results from the REVIVE study, how do you foresee Rusfertide fitting into the future treatment landscape for polycythemia vera?
Added By: kyle_adminCan you discuss the significance of the real-world data presented on the prevalence of secondary cancers in PV patients, particularly in the context of treatment choices and the potential role of Rusfertide?
Added By: kyle_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
